Immune Checkpoint Inhibitor Dermatologic Toxicities
Summary
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy by unleashing antitumour immunity through blockade of regulatory molecules such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Despite their efficacy, these agents frequently induce immune-related adverse events (irAEs) affecting the skin, which represent the most common and often earliest manifestation. Presentations range from mild maculopapular rash and pruritus to severe forms such as lichenoid and psoriasiform eruptions, bullous pemphigoid and, in rare cases, Stevens-Johnson syndrome or toxic epidermal necrolysis. The underlying mechanisms involve inadvertent activation of autoreactive T cells, cross-reactivity between tumour and cutaneous antigens, and heightened proinflammatory cytokine release. Recognition of dermatologic irAEs is crucial not only for symptom control and quality of life but also as a potential biomarker of therapeutic response. Management strategies span topical corticosteroids and symptomatic care for low-grade reactions, through to systemic immunosuppression and treatment interruption for life-threatening toxicity. Coordination between oncologists and dermatologists enables continuation of life-saving immunotherapy whenever feasible.
Research from Nature Portfolio
Recent mechanistic studies have elucidated the role of PD-1 signalling in restraining cutaneous inflammation. Experiments in murine models demonstrate that loss of PD-1 on CD8 T cells drives an exaggerated psoriasiform dermatitis via cross-talk with keratinocytes and induction of interleukin 6. Blockade of IL-6 signalling attenuates the epidermal infiltration and inflammatory cascade, suggesting a targeted approach to treat severe rash without compromising antitumour effects.
Immune Checkpoint Inhibitor Dermatologic Toxicities publication trend
The graph below shows the total number of articles in immune checkpoint inhibitor dermatologic toxicities across all publications each year (not limited to Nature Index journals).
Technical terms
Immune checkpoint inhibitor (ICI): A monoclonal antibody that blocks regulatory receptors on T cells to enhance antitumour immunity.
Immune-related adverse event (irAE): An unintended inflammatory reaction in normal tissues triggered by immune therapies.
Maculopapular rash: A skin eruption combining flat discoloured spots (macules) and small raised bumps (papules).
Bullous pemphigoid: An autoimmune blistering skin disorder characterised by subepidermal fluid-filled vesicles.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): Severe, potentially life-threatening mucocutaneous reactions with widespread skin detachment.
Psoriasiform eruption: A rash resembling psoriasis with red, scaly plaques.
References
- Cutaneous manifestations associated with immune checkpoint inhibitors. Frontiers in Immunology (2023).
- Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's Adverse Event Reporting System dataset. Journal of the American Academy of Dermatology (2024).
- Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Communications Biology (2020).
- Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors. British Journal of Dermatology (2021).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.